Table 2 Comparison between the cervical and non-cervical lesion groups (univariate analysis)
Cervical lesion group (n = 106) | Non-cervical lesion group (n = 79) | P-value* | |
|---|---|---|---|
Sex (n) (male:female) | 6:100 | 6:73 | 0.60 |
Age (years) (IQR) | 68 (62−73) | 68 (62−75) | 0.66 |
Age of onset (years) | 48 (39−59) | 59 (50−68) | < 0.01 |
RA disease duration (years) (IQR) | 15 (8−26) | 6 (2−13) | < 0.01 |
CRP level (mg/dL) (IQR) | 0.4 (0.1−1.3) | 0.2 (0.1−0.8) | 0.06 |
RF positive (n) | 62 % (66/106) | 62 % (49/79) | 0.97 |
MMP3 positive (n) | 64 % (68/106) | 67 % (53/79) | 0.68 |
DAS28-CRP (IQR) | 2.3 (1.9−3.0) | 2.1 (1.6−3.1) | 0.76 |
RA stage III or IV (n) | 88 % (93/106) | 46 % (36/79) | < 0.01 |
Prednisolone (n) | 58 % (61/106) | 37 % (29/79) | < 0.01 |
MTX (n) | 60 % (64/106) | 66 % (52/79) | 0.45 |
Biological agents (n) | 53 % (56/106) | 19 % (15/79) | < 0.01 |
BMD of the lumbar spine (YAM) (IQR) | 79 (70−91) | 86 (78−95) | 0.09 |
BMD of the femoral neck (YAM) (IQR) | 64 (57−72) | 72 (64−81) | < 0.01 |
Previous joint surgery (n) | 41 % (43/106) | 23 % (18/79) | 0.01 |